Jensen_etal_2022_molecular_dynamics_simulation_data_2
By onFull molecular dynamics simulation data set accompanying Jensen et al, 2022, containing (i) representative coordinates and measurements described therein, (ii) simulation trajectories, and (iii) GROMACS input files.
Phosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits
By onStudy shows increasing PGK1 gene expression enhances neuronal ATP production, protecting against synaptic dysfunction in Parkinson's disease. Boosting bioenergetics with PGK1 may be a promising therapeutic approach for PD.
iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP
By onImproved iATPSnFR2 sensor offers real-time ATP level monitoring in cells. Enhanced dynamic range, high specificity, and subcellular targeting capabilities enable detailed metabolic analysis in different cellular regions.
Adaptor protein-3 produces synaptic vesicles that release phasic dopamine
By onThe burst firing of midbrain dopamine neurons releases a phasic dopamine signal that mediates reinforcement learning. At many synapses, however, high firing rates deplete synaptic vesicles (SVs), resulting in synaptic depression that limits release. What accounts for the increased release of dopamine by stimulation at high frequency? We find that adaptor protein-3 (AP-3) and its coat protein VPS41 promote axonal dopamine release by targeting vesicular monoamine transporter VMAT2 to the axon rather than dendrites. AP-3 and VPS41 also produce SVs that respond preferentially to high-frequency stimulation, independent of their role in axonal polarity. In addition, conditional inactivation of VPS41 in dopamine neurons impairs reinforcement learning, and this involves a defect in the frequency dependence of release rather than the amount of dopamine released. Thus, AP-3 and VPS41 promote the axonal polarity of dopamine release but enable learning by producing a distinct population of SVs tuned specifically to high firing frequency that confers the phasic release of dopamine.
Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l-DOPA–induced dyskinetic behaviors
By onImbalances in dopamine and acetylcholine affect motor function in Parkinson's disease. Contrary to conventional theories, reduced cholinergic transmission at M4 receptors in dopamine-depleted mice alleviated motor deficits and dyskinetic behavior.
Systems-level analyses dissociate genetic regulators of reactive oxygen species and energy production
By onRespiratory chain dysfunction affects ATP and ROS levels. Knockdown of genes in specific respiratory complexes increases ROS, while metabolic conditions have little impact on ROS. Ether lipids play a role in regulating ROS independently of ATP.
Transfection by electroporation of GFP-LRRK2 and Immunofluorescent imaging of MEFs VPS35 (D620N) mutants stably expressing LysoTag
By onThe authors investigated the colocalization of GFP-LRRK2 with a lysosomal localized TMEM192-3xHA.
Primary data associated with the manuscript 10.1073/pnas.2315171120 (“Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis”)
By onPrimary data associated with the manuscript 10.1073/pnas.2315171120 ("Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis").
Single-cell somatic copy number variants in brain using different amplification methods and reference genomes
By onSomatic mutations in the brain are well-known, requiring single-cell whole genome amplification before sequencing. PicoPLEX, MDA, and PTA whole genome amplification methods were compared on brain nuclei, showing different properties.
Lentiviral vector plasmid for knock down of ATP10B (miR5 Hs)
By onLentiviral vector plasmid for knock down of ATP10B (miR5, Hs) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (I1038T)
By onLentiviral vector plasmid for overexpression of ATP10B (I1038T) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (G671R/N865K)
By onLentiviral vector plasmid for overexpression of ATP10B (G671R/N865K) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (E993A)
By onLentiviral vector plasmid for overexpression of ATP10B (E993A) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (V748L)
By onLentiviral vector plasmid for overexpression of ATP10B (V748L) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (R153X)
By onLentiviral vector plasmid for overexpression of ATP10B (R153X) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (EmGFP)
By onLentiviral vector plasmid for overexpression of ATP10B (EmGFP) validated for use in cell culture
Lentiviral vector plasmid for overexpression of ATP10B (E210A)
By onLentiviral vector plasmid for overexpression of ATP10B (E210A) validated for use in cell culture
Membrane and cytosol fractionation
By onThis protocol describes membrane and cytosol fractionation of cells expressing different DNAJC5 isoforms.
CRISPR/Cas9 genome editing
By onThis protocol describes the generation of DNAJC5 KO using CRISPR/Cas9 edition
In vitro depalmitoylation assay
By onThis protocol describes the in vitro depalmitoylation assay of DNAJC5.